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curred by hypertensive patients in this employer’s popu-
lation were extracted from medical and pharmacy claims
data for the period October 1, 1996 to September 30,
1997. Hypertension medication compliance for each pa-
tient in the same population was calculated based on the
medication possession rate (MPR  number of days sup-
plied for the single longest prescribed anti-hypertensive
drug for the study year/365 days). A patient who had an
MPR of 80% was considered noncompliant while an
MPR of 80% was considered compliant. RESULTS:
The prevalence rate of hypertension in this employer’s
population (12.6%) was higher than the comparative
MedStat population (9.7%). Of these, 31.1% had hyper-
cholesterolemia and 11.2% had ischemic heart disease in
addition to their hypertension. All resource utilization
rates and direct costs of hypertensive patients in this em-
ployer’s population were higher than those of the com-
parative MedStat population. For example, the cardio-
vascular-related utilization rates for outpatient visits,
hospitalizations, and ER visits were 185.8 (MedStat 
171.3), 12.8 (MedStat  3.5), and 3.3 (MedStat  1.5)
per 1000 members per year, respectively. The total direct
cost payment was approximately $4,833 per hyperten-
sion patient per year, again higher than MedStat’s $3,721
per annual patient cost. Of the 4,924 hypertensive pa-
tients included in these analyses 2,379 (48.3%) were
identified as noncompliant and 2,545 (51.7%) were com-
pliant. CONCLUSIONS: These results were presented to
the employer’s senior management to help them priori-
tize their health management initiatives. A hypertension
disease management program has been developed for this
population and will be implemented first quarter of
2000.
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OBJECTIVE: To assess the trends in the economic bur-
den of illness for the treatment of patients with schizo-
phrenia over a three-year period. METHODS: We esti-
mated the annual per patient direct costs of treatment for
schizophrenia during 1995–1997 in a large administra-
tive claims database (LifeLinkTM) representing approxi-
mately 1.6 million covered lives. Diagnosis-related and
other medical expenditures were estimated for patients
with a diagnosis of schizophrenia. The estimated costs of
care included expenditures for hospitalization, hospital
outpatient services, outpatient medications, psychiatric
day/night facilities, nursing home facilities, office visits,
ER visits, laboratory tests, substance abuse treatment,
and other services. All costs are expressed in 1997 dol-
lars. RESULTS: The prevalence rate of schizophrenia in
the database was 3.2 patients per 1,000 eligible members.
The average annual total cost of care, including medica-
tions, for patients with schizophrenia declined by 15 per-
cent between 1995 and 1997, from $14,612 to $12,435.
Annual patient expenditures for outpatient antipsychotic
medications of interest increased by 48 percent from
$994 in 1995 to $1,474 in 1997, and represented 11.9
percent of total costs in 1997. Annual costs incurred for
services directly associated with a diagnosis of schizo-
phrenia, excluding outpatient medications, declined by
$2,564 (38 percent) between 1995 and 1997. The major-
ity of this reduction was accounted for by services associ-
ated with institutional care. CONCLUSIONS: The total
direct costs of care for patients with schizophrenia in this
study declined between 1995–1997. Increases in the costs
incurred for antipsychotic medications were primarily
offset by declines in other diagnosis-related expenditures.
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OBJECTIVE: The economic burden of illness for the
treatment of bipolar disorder is poorly understood. We
estimated the annual per patient cost of care for individu-
als with this diagnosis in a large population and evalu-
ated trends in cost over a three-year period beginning in
1995. METHODS: We examined the direct costs of care
for bipolar disorder in an employer claims database (Life-
LinkTM) representing the health care experience of ap-
proximately 1.6 million covered lives. The estimated
costs of care included expenditures for hospitalization,
hospital outpatient services, outpatient medications, psy-
chiatric day/night facilities, nursing home facilities, office
visits, ER visits, laboratory tests, substance abuse treat-
ment, and other services. Outpatient medication costs
were separately estimated for mood stabilizers and anti-
psychotic therapies of interest and other outpatient medi-
cation costs. All costs were inflation-adjusted to 1997
dollars. RESULTS: The prevalence of bipolar disorder in
the population was 5.5 patients per 1000 eligible mem-
bers. These patients incurred significant annual expendi-
tures, totaling $13,402 in 1995, $11,856 in 1996, and
$11,146 in 1997. These expenditures were comparable
to the costs of treatment for schizophrenia in the same
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population during this period. Annual costs for outpa-
tient use of mood stabilizers and antipsychotic medica-
tions increased by $168 (42%) over the study interval,
totaling $565 in 1997. However, other costs of care for
these patients decreased by $2,424 during the same pe-
riod; more than 80 percent ($2,007) of this decline was
accounted for by costs incurred for services directly asso-
ciated with receipt of a diagnosis of bipolar disorder.
CONCLUSIONS: Treatment of bipolar disorder imposes
a significant economic burden to the health care system.
The increasing availability and use of novel and more ex-
pensive mood stabilizing and antipsychotic medications
for treatment of bipolar disorder does not appear to have
resulted in an increase in the total costs of the disease.
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OBJECTIVE: The purpose of the study was to examine
formal care costs (direct medical costs) and informal care
costs (non-reimbursed caregiver time) of Alzheimer’s pa-
tients enrolled in an integrated managed care organiza-
tion (MCO). METHODS: The MCO provided medical
and prescription claims data for a one-year period for 80
patients diagnosed with Alzheimer’s disease (AD) or re-
lated dementia. Severity measurements were made at
baseline, month 6, and month 12. Caregivers provided
informal care information three times throughout the
year. RESULTS: The mean annual cost of care for these
AD patients was $36,850.94 (sd  18,356.62). There
was a mean of $26,434.12 (sd  20,239.38) for formal
care costs (71.7%), and a mean of $10,416.82 (sd 
8,962.07) for informal care costs (28.3%). Costs were
calculated for patients with mild, moderate, and severe
AD, as well as for patients who lived in the community,
in institutions, and moved from community to institu-
tion. Mean annual costs were approximately 1.8 and 1.2
times higher for severe patients than for mild and moder-
ate patients, respectively. Mean annual formal care costs
were 14.3 times higher for institutionalized patients than
for those in the community. Mean annual informal costs
were 2.2 times higher for community patients than insti-
tutionalized patients. CONCLUSIONS: Through de-
tailed cost analyses, managed care decision-makers can
be better informed about the current care being provided
for AD patients. The total annual direct medical cost was
$2.1 million for these 80 managed care patients with AD.
With the increasing prevalence of AD and the higher
costs associated with the advancement of the disease,
managed care would benefit by providing treatment that
could delay or reverse the progression of AD.
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OBJECTIVE: To describe outpatient antipsychotic medica-
tion treatment patterns and estimate the diagnosis-related
costs of care associated with treatment of schizophrenic
patients in usual care. METHODS: Use of outpatient an-
tipsychotic medications and other health services during
1997 was obtained for 1,356 patients with a diagnosis of
schizophrenia in a claims database. We evaluated the
treated prevalence of outpatient antipsychotic therapy
and continuity of medication usage, and estimated the
costs of schizophrenia care, adjusting for multiple co-
variates. RESULTS: 21.2% of patients diagnosed with
schizophrenia received no antipsychotic medication in
the outpatient setting for a minimum of 12 months after-
ward; 19.2% discontinued their initial antipsychotic
without subsequent restart of an antipsychotic during the
interval; 20.9% experienced multiple treatment episodes
of the same antipsychotic; 17.8% received multiple dif-
ferent antipsychotic medications; and 20.9% received
continuous antipsychotic medication therapy. Patients re-
ceiving multiple antipsychotics incurred significantly
higher total diagnosis-related costs (P  0.001) than pa-
tients in each of the other medication treatment groups.
The average diagnosis-related cost of care for patients re-
ceiving multiple antipsychotics was $10,585, $5,692 for
patients who discontinued monotherapy without re-
start, $5,156 for patients with continuous monotherapy,
$5,068 for patients with multiple monotherapy treatment
episodes, and $2,401 for patients not receiving medica-
tion therapy. The proportion of costs for institutional
care incurred by patients ranged from 37% for patients
receiving continuous medication monotherapy to 77%
for patients who either discontinued or never received
medication therapy. CONCLUSIONS: A substantial pro-
portion of schizophrenic patients received either no expo-
sure or limited exposure to antipsychotic medications.
Patients who received medication monotherapy either
continuously or through successive treatment episodes
were less costly than patients who received multiple med-
ication therapies or discontinued medication monother-
apy. Reductions in institutional costs among patients re-
ceiving continuous antipsychotic monotherapy offset costs
of these medications.
